We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-5.51%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$285M
AUM Growth
-$94.6M
(-25%)
Cap. Flow
-$78.6M
Cap. Flow
% of AUM
-27.58%
Top 10 Holdings %
Top 10 Hldgs %
56.44%
Holding
82
New
19
Increased
11
Reduced
16
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$17M |
| 2 |
Qiagen
QGEN
|
+$15.8M |
| 3 |
Icon
ICLR
|
+$11.1M |
| 4 |
Zoetis
ZTS
|
+$7.11M |
| 5 |
Baxter International
BAX
|
+$6.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$15.9M |
| 2 |
Orthofix Medical
OFIX
|
+$14.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$14.2M |
| 4 |
Centene
CNC
|
+$12.5M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$9.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alnylam Pharmaceuticals
ALNY
$30.5B
| – | – |
-10,379
| Closed | -$1.7M |
|
52
argenx
ARGX
$54B
| – | – |
-4,480
| Closed | -$1.41M |
|
|
53
AstraZeneca
AZN
$250B
| – | – |
-120,136
| Closed | -$15.9M |
|
|
54
Bristol-Myers Squibb
BMY
$130B
| – | – |
-194,684
| Closed | -$14.2M |
|
55
CareDx
CDNA
$2.4B
| – | – |
-28,048
| Closed | -$1.04M |
|
56
Charles River Laboratories
CRL
$12.3B
| – | – |
-3,308
| Closed | -$939K |
|
57
DarioHealth
DRIO
$71.5M
| – | – |
-3,689
| Closed | -$431K |
|
58
PUT
DaVita
DVA
$12.1B
| – | – |
-10,000
| Closed | -$1.13M |
|
59
Encompass Health
EHC
$11B
| – | – |
-82,526
| Closed | -$4.67M |
|
60
Edwards Lifesciences
EW
$51.1B
| – | – |
-44,561
| Closed | -$5.25M |
|
61
Gossamer Bio
GOSS
$87.9M
| – | – |
-68,710
| Closed | -$596K |
|
62
ICU Medical
ICUI
$4.17B
| – | – |
-6,093
| Closed | -$1.36M |
|
63
Idexx Laboratories
IDXX
$46.2B
| – | – |
-5,729
| Closed | -$3.13M |
|
64
Iovance Biotherapeutics
IOVA
$1.98B
| – | – |
-60,720
| Closed | -$1.01M |
|
65
Intuitive Surgical
ISRG
$132B
| – | – |
-17,232
| Closed | -$5.2M |
|
|
KZR
66
DELISTED
Kezar Life Sciences
KZR
| – | – |
-5,947
| Closed | -$988K |
|
67
Mettler-Toledo International
MTD
$28.5B
| – | – |
-1,765
| Closed | -$2.42M |
|
68
Natera
NTRA
$39.3B
| – | – |
-24,747
| Closed | -$1.01M |
|
|
69
Orthofix Medical
OFIX
$422M
| – | – |
-434,803
| Closed | -$14.2M |
|
|
PINC
70
DELISTED
Premier
PINC
| – | – |
-75,632
| Closed | -$2.69M |
|
71
Rhythm Pharmaceuticals
RYTM
$7.53B
| – | – |
-105,792
| Closed | -$1.22M |
|
72
Tandem Diabetes Care
TNDM
$1.33B
| – | – |
-18,236
| Closed | -$2.12M |
|
73
10x Genomics
TXG
$6.05B
| – | – |
-24,923
| Closed | -$1.9M |
|
74
Viridian Therapeutics
VRDN
$2.32B
| – | – |
-83,217
| Closed | -$1.54M |
|
75
Vertex Pharmaceuticals
VRTX
$123B
| – | – |
-6,982
| Closed | -$1.82M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Endurant Capital Management held 82 positions worth $285M, down 25% from $380M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Endurant Capital Management withdrew a net $78.6M in Q2 2022, closing 32 positions and reducing 16 holdings. Its most notable exit was AstraZeneca, an estimated $15.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 70% a quarter earlier.
Against the trend, Endurant Capital Management opened a new position in Boston Scientific worth $15.6M.
- Endurant Capital Management's largest Q2 2022 buy was Boston Scientific: 418,165 shares worth $15.6M.
- Endurant Capital Management added most to Qiagen in Q2 2022, an estimated $15.8M increase.
- Endurant Capital Management's biggest Q2 2022 reduction was Centene, cutting an estimated $12.5M.
- Endurant Capital Management fully exited AstraZeneca in Q2 2022, selling an estimated $15.9M.
- Endurant Capital Management's ten largest holdings make up 56% of its $285M portfolio in Q2 2022.
- Endurant Capital Management opened 19 new positions and closed 32 in Q2 2022.
- Endurant Capital Management's portfolio value fell 25% quarter-over-quarter to $285M.
Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.